Literature DB >> 9098014

Effects of ethanol consumption on hepatic hemodynamics in patients with alcoholic cirrhosis.

A Luca1, J C García-Pagán, J Bosch, F Feu, J Caballería, R J Groszmann, J Rodés.   

Abstract

BACKGROUND & AIMS: Increased portal blood flow represents a compensatory mechanism preventing hepatic hypoxia after ethanol consumption. In addition, alcohol increases hepatic vascular resistance. Thus, ethanol consumption, by increasing hepatic vascular resistance and portal flow, may worsen portal hypertension in patients with cirrhosis. The aim of this study was to investigate the effects of ethanol consumption on hepatic hemodynamics in patients with alcohol-induced cirrhosis.
METHODS: Measurements of hepatic venous pressure gradient (HVPG), azygos blood flow, hepatic blood flow, heart rate, and arterial pressure were obtained in 16 patients with alcohol-induced cirrhosis and portal hypertension before and after random administration of a noncaloric fruit drink (250 mL, n = 7) or of an identical beverage plus 0.5 g/kg of ethanol (n = 9).
RESULTS: Vehicle caused no effects. By contrast, ethanol increased HVPG (P < 0.0001). The increase in HVPG was maximum at 15 minutes and remained significant at 45 minutes (P < 0.05 vs. vehicle). Ethanol increased azygos blood flow (P < 0.05) without changes in hepatic blood flow. Heart rate and arterial pressure slightly increased.
CONCLUSIONS: Oral ethanol consumption increases portal pressure and portocollateral blood flow in patients with alcohol-induced cirrhosis. These findings suggest that even moderate alcohol consumption worsens the portal-hypertensive syndrome and, therefore, may increase the risk of variceal bleeding in patients with alcohol-induced cirrhosis.

Entities:  

Mesh:

Year:  1997        PMID: 9098014     DOI: 10.1016/s0016-5085(97)70142-2

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  28 in total

Review 1.  Current management of the complications of portal hypertension: variceal bleeding and ascites.

Authors:  Nina Dib; Frédéric Oberti; Paul Calès
Journal:  CMAJ       Date:  2006-05-09       Impact factor: 8.262

Review 2.  Role of variability in explaining ethanol pharmacokinetics: research and forensic applications.

Authors:  Ake Norberg; A Wayne Jones; Robert G Hahn; Johan L Gabrielsson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

3.  Influence of extravariceal collateral channel pattern on recurrence of esophageal varices after sclerotherapy.

Authors:  T Sakai; T Iwao; K Oho; A Toyonaga; K Tanikawa
Journal:  J Gastroenterol       Date:  1997-12       Impact factor: 7.527

Review 4.  Impact of etiological treatment on prognosis.

Authors:  Chien-Wei Su; Ying-Ying Yang; Han-Chieh Lin
Journal:  Hepatol Int       Date:  2017-07-12       Impact factor: 6.047

Review 5.  Optimal management for alcoholic liver disease: Conventional medications, natural therapy or combination?

Authors:  Moon-Sun Kim; Madeleine Ong; Xianqin Qu
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 6.  Alcoholic liver disease.

Authors:  K Walsh; G Alexander
Journal:  Postgrad Med J       Date:  2000-05       Impact factor: 2.401

Review 7.  Microbiota-based treatments in alcoholic liver disease.

Authors:  Hotaik Sung; Seung Woo Kim; Meegun Hong; Ki Tae Suk
Journal:  World J Gastroenterol       Date:  2016-08-07       Impact factor: 5.742

Review 8.  Therapy for alcoholic liver disease.

Authors:  Maryconi M Jaurigue; Mitchell S Cappell
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

9.  Development of hypoxemia in alcoholic liver disease.

Authors:  Shigeo Maruyama; Chisato Hirayama; Kazunori Maeda; Satoru Yamamoto; Masaharu Koda; Akihide Udagawa; Masayuki Inoue; Kensuke Umeki
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

10.  Management of Alcohol Use Disorder in Patients Requiring Liver Transplant.

Authors:  Mary R Lee; Lorenzo Leggio
Journal:  Am J Psychiatry       Date:  2015-12       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.